Table 1 Baseline characteristics of study subjects
From: Microvascular dysfunction in schizophrenia: a case–control study
Schizophrenia; N (%) | Control; N (%) | P-value | |
|---|---|---|---|
Total sample | 51 | 51 | — |
Male | 30 (58.8) | 30 (58.8) | >0.999 |
Female | 21 (41.2) | 21 (41.2) | >0.999 |
Caucasian ethnicity | 33 (64.7) | 38 (74.5) | 0.110 |
Cardiovascular risk factors | |||
Hypertension | 2 (3.9) | 0 (0) | 0.160 |
Diabetes | 2 (3.9) | 1 (2.0) | 0.558 |
Dyslipidemia | 10 (19.6) | 2 (3.9) | 0.014 |
Current smokers | 23 (45.1) | 22 (43.1) | 0.842 |
Family history of CVD | 20 (39.2) | 19 (37.2) | 0.839 |
Metabolic syndrome (ATP III definition) a | 15 (29.4) | 3 (5.9) | 0.002 |
Psychotropic medications | |||
Antipsychotic medication use | 51 (100) | n/a | |
Antidepressant medication use | 14 (27.4) | n/a | — |
Mood stabilizers | 7 (13.7) | n/a | — |
Benzodiazepines | 5 (9.8) | n/a | — |
Anticholinergic medication use | 6 (11.8) | n/a | — |
Other medications | |||
Antihypertensive medication use | 6 (11.8) | 0 (0) | 0.012 |
Lipid-lowering medication use | 9 (17.7) | 0 (0) | 0.002 |
Antidiabetic medication use | 2 (3.9) | 0 (0) | 0.160 |
Mean | s.d. | Mean | s.d. | ||
|---|---|---|---|---|---|
Age (years) | 35.1 | 7.1 | 33.9 | 7.9 | 0.442 |
Disease duration (years) | 13.5 | 6.8 | n/a | — | |
Mean body mass index (kg/m2) | 30.7 | 7.5 | 24.9 | 4.7 | <0.001 |
Waist circumference (cm) | 101.0 | 15.0 | 80.6 | 12.0 | <0.001 |
Systolic blood pressure (mm HG) | 114.5 | 11.9 | 117.7 | 12.5 | 0.186 |
Diastolic blood pressure (mm HG) | 75.2 | 8.6 | 73.9 | 8.1 | 0.443 |
Pack years of smoking | 7.32 | 8.117 | 2.259 | 4.302 | <0.001 |
Median | 25th, 75th percentile | Median | 25th, 75th percentile | ||
|---|---|---|---|---|---|
Total physical activity (MET*min/week) | 1,830 | (1,094, 3,545) | 2,680 | (1,201, 7,011) | 0.115 |
